Katherine Bao

Eli Lilly (United States) — United States

Medicine · Health Sciences

14h-index1.5kcitations36works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(11), Lymphoma Diagnosis and Treatment(7), Immune Cell Function and Interaction(7), IL-33, ST2, and ILC Pathways(7), Chronic Myeloid Leukemia Treatments(6)

Publications36 total

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology·2025· 1 citedOpen Access
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology·2025· 2 citedOpen Access
Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients
Blood·2025· 2 citedOpen Access
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
Blood·2025
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Blood·2025Open Access
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Journal of Clinical Oncology·2025· 1 cited
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Journal of Clinical Oncology·2025· 1 cited
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Journal of Clinical Oncology·2025· 21 citedOpen Access
BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Blood·2024· 17 citedOpen Access
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Haematologica·2024· 11 citedOpen Access
Sox4 Promotes Atoh1-Independent Intestinal Secretory Differentiation Toward Tuft and Enteroendocrine Fates
UNC Libraries·2024Open Access
P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
HemaSphere·2023· 4 citedOpen Access
A bifurcated role for c-Maf in Th2 and Tfh2 cells during helminth infection
Mucosal Immunology·2023· 5 citedOpen Access
Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Blood·2022· 4 cited
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Blood·2022· 28 cited
CLL-129 BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
Poster: CLL-129 BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
Clinical Lymphoma Myeloma & Leukemia·2022
Activation-Induced Cytidine Deaminase Impacts the Primary Antibody Repertoire in Naive Mice
The Journal of Immunology·2022· 2 citedOpen Access
BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
Blood·2021· 2 cited
Kinase inhibition in autoimmunity and inflammation
Nature Reviews Drug Discovery·2020· 399 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Wojciech Jurczak(16), R. Lee Reinhardt(12), Ching Ching Leow(9), Catherine C. Coombs(8), Talha Munir(7), Amy S. Ruppert(6), Sebastian Grosicki(6), Lindsey E. Roeker(6), Vu Minh Hua(6), Marisa Hill(6), Paolo Ghia(6), Manish R. Patel(5), Toby A. Eyre(5), Shuo Ma(5), Jonathon B. Cohen(5), Krish Patel(5), Jennifer R. Brown(5), Ewa Lech‐Marańda(5), Marc Hoffmann(5), Chaitra S. Ujjani(5)